Pharmaceutical

Biogen’s higher Spinraza dose shows better efficacy in Phase II/III trial 

Biogen plans to apply for regulatory approval of this investigational dose regimen following positive trial data.

Sep 8, 2024 - 04:00
Biogen’s higher Spinraza dose shows better efficacy in Phase II/III trial 
Biogen plans to apply for regulatory approval of this investigational dose regimen following positive trial data.
Read the original article

Tags:

Previous Article

Onward awarded $1.1M grant from the Christopher & Dana Reeve Foundation to advan...

Next Article

After failed FSGS bid, Travere wins full FDA approval for Filspari in IgAN

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Verastem files patent for combination treatment of FAK ...

Mar 24, 2024

A rare disease has run through five generations of his family, so he’s built community for others

A rare disease has run through five generations of his ...

Jul 10, 2023

UK Government to launch first ever men’s health strategy

UK Government to launch first ever men’s health strategy

Dec 1, 2024